The US Food and Drug Administration (FDA) has announced that it has issued more than 889,000 Refuse to Accept (RTA) letters as of October 7, to pre-market tobacco product applications (PMTAs) that do not meet acceptance criteria.
The organization also announced that the FDA has received over 1,600 applications, the majority of which are for electronic cigarettes or e-liquid products.
Although the review process is ongoing, the FDA remains vigilant in regulating the market and will continue to use our compliance and enforcement resources to curb the illegal marketing of non-tobacco nicotine products. To date, the FDA has issued more than 60 warning letters to manufacturers, including popular brands among young people such as Puff Bar," stated the FDA in a press release. "The warning letters include products that have submitted applications but have received negative actions from the agency.
The FDA has sent over 300 warning letters to retailers demanding that they cease selling synthetic nicotine e-cigarette products to minors, and has imposed civil fines on two retailers for selling e-cigarette products to minors.
So far, the FDA has not authorized any synthetic nicotine e-cigarette products. Therefore, all synthetic nicotine e-cigarette products on the market are being sold illegally and are at risk of FDA enforcement action," said the FDA. "Retailers or distributors selling or distributing unauthorized e-cigarettes are breaking the law and those engaging in such behavior will face FDA enforcement risks, such as seizures, injunctions, or civil fines.
Statement:
This article is compiled from third-party information and is intended for industry exchange and learning purposes.
This article does not represent the views of 2FIRSTS and 2FIRSTS is unable to confirm the truthfulness and accuracy of the content. The translation of this article is solely for industry exchange and research purposes.
Due to limitations in our translation abilities, the translated article may not fully represent the original text. Therefore, please refer to the original text for accurate information.
2FIRSTS maintains complete alignment with the Chinese government regarding any domestic, Hong Kong, Macau, Taiwan, and foreign-related statements and positions.
The ownership of compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
